All Stories

  1. Ixekizumab—An Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P

    Article • Journal of Psoriasis and Psoriatic Arthritis, August 2019, SAGE Publications

    Dr Kim A Papp

  2. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies

    Article • Journal of Cutaneous Medicine and Surgery, November 2018, SAGE Publications

    Dr Kim A Papp, Dr Don VINH

  3. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis

    Article • British Journal of Dermatology, October 2018, Wiley

    Dr Kim A Papp

  4. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials

    Article • British Journal of Dermatology, July 2018, Wiley

    Dr Kim A Papp

  5. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

    Article • British Journal of Dermatology, May 2018, Wiley

    Dr Kim A Papp

  6. Response to ‘Psoriasis patients’ preference for an aerosol foam topical formulation’ by Vender R et al .

    Article • Journal of the European Academy of Dermatology and Venereology, May 2018, Wiley

    Dr Kim A Papp

  7. Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis

    Article • Biopharmaceutics & Drug Disposition, April 2018, Wiley

    Dr Kim A Papp

  8. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

    Article • Journal of the European Academy of Dermatology and Venereology, April 2018, Wiley

    Dr Kim A Papp

  9. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

    Article • British Journal of Dermatology, February 2018, Wiley

    Dr Kim A Papp

  10. OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States

    Article • Journal of Cutaneous Medicine and Surgery, February 2018, SAGE Publications

    Dr Kim A Papp

  11. Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P)

    Article • British Journal of Dermatology, February 2018, Wiley

    Dr Kim A Papp

  12. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis

    Article • British Journal of Dermatology, December 2017, Wiley

    Dr Kim A Papp

  13. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices

    Article • Journal of Cutaneous Medicine and Surgery, October 2017, SAGE Publications

    Dr Kim A Papp

  14. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study

    Article • Journal of the European Academy of Dermatology and Venereology, September 2017, Wiley

    Dr Kim A Papp

  15. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab

    Article • British Journal of Dermatology, July 2017, Wiley

    Dr Kim A Papp, David Harris Collier

  16. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial

    Article • The Journal of Dermatology, July 2017, Wiley

    Dr Kim A Papp

  17. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis

    Article • Journal of the European Academy of Dermatology and Venereology, June 2017, Wiley

    Dr Kim A Papp

  18. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

    Article • British Journal of Dermatology, June 2016, Wiley

    Dr Kim A Papp

  19. A randomized phase 2b trial of baricitinib, an oral Janus kinase ( JAK ) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis

    Article • British Journal of Dermatology, April 2016, Wiley

    Dr Kim A Papp

  20. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

    Article • British Journal of Dermatology, October 2015, Wiley

    Dr Kim A Papp

  21. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

    Article • British Journal of Dermatology, October 2015, Wiley

    Dr Kim A Papp

  22. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Article • The Lancet, August 2015, Elsevier

    Dr Kim A Papp, Dr Ronald Vender

  23. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Article • Journal of the American Academy of Dermatology, July 2015, Elsevier

    Dr Kim A Papp

  24. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

    Article • British Journal of Dermatology, June 2015, Wiley

    Dr Kim A Papp

  25. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis

    Article • BMC Dermatology, May 2015, Springer Science + Business Media

    Dr Kim A Papp

  26. Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept

    Article • Journal of Cutaneous Medicine and Surgery, May 2015, SAGE Publications

    Dr Kim A Papp

  27. ESTEEM 1: Apremilast Safety Acceptable After 2 Years Exposure

    Article • MD Conference Express, April 2015, CLOCKSS Archive

    Dr Kim A Papp

  28. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis

    Article • Journal of the American Academy of Dermatology, March 2015, Elsevier

    Dr Kim A Papp

  29. Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

    Article • Journal of the European Academy of Dermatology and Venereology, January 2015, Wiley

    Dr Kim A Papp

  30. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    Article • New England Journal of Medicine, July 2014, New England Journal of Medicine (NEJM/MMS)

    Dr Kim A Papp, Dr Ronald Vender

  31. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis ( REFINE )

    Article • Journal of the European Academy of Dermatology and Venereology, July 2014, Wiley

    Dr Kim A Papp

  32. Effect of ixekizumab treatment on scalp psoriasis: Results from a phase 2 study in patients with moderate to severe psoriasis

    Article • Journal of the American Academy of Dermatology, May 2014, Elsevier

    Dr Kim A Papp

  33. Impact of baseline characteristics on the efficacy of ixekizumab in patients with moderate to severe psoriasis in a phase 2 study

    Article • Journal of the American Academy of Dermatology, May 2014, Elsevier

    Dr Kim A Papp

  34. A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

    Article • British Journal of Dermatology, July 2013, Wiley

    Dr Kim A Papp

  35. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

    Article • Journal of the European Academy of Dermatology and Venereology, May 2013, Wiley

    Dr Kim A Papp

  36. Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

    Article • CPT Pharmacometrics & Systems Pharmacology, May 2013, Wiley

    Dr Kim A Papp

  37. Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

    Article • Journal of the European Academy of Dermatology and Venereology, March 2013, Wiley

    Dr Kim A Papp

  38. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

    Article • British Journal of Dermatology, January 2013, Wiley

    Dr Kim A Papp

  39. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

    Article • Health and Quality of Life Outcomes, January 2013, Springer Science + Business Media

    Dr Kim A Papp

  40. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

    Article • Journal of the European Academy of Dermatology and Venereology, October 2012, Wiley

    Dr Kim A Papp

  41. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

    Article • Arthritis & Rheumatism, September 2012, Wiley

    Dr Kim A Papp

  42. A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

    Article • British Journal of Dermatology, August 2012, Wiley

    Dr Kim A Papp

  43. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

    Article • The Lancet, August 2012, Elsevier

    Dr Kim A Papp

  44. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

    Article • Journal of the European Academy of Dermatology and Venereology, March 2012, Wiley

    Dr Kim A Papp

  45. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

    Article • Journal of the American Academy of Dermatology, February 2012, Elsevier

    Dr Kim A Papp

  46. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

    Article • Arthritis & Rheumatism, January 2012, Wiley

    Dr Kim A Papp

  47. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study

    Article • Journal of the European Academy of Dermatology and Venereology, October 2011, Wiley

    Dr Kim A Papp

  48. The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

    Article • American Journal of Clinical Dermatology, October 2011, Springer Science + Business Media

    Dr Kim A Papp

  49. Long-term, continuous dosing of etanercept in patients with plaque psoriasis

    Article • Expert Review of Dermatology, August 2011, Taylor & Francis

    Dr Kim A Papp, Professor Gregor B Jemec

  50. Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet

    Article • Archives of Dermatology, April 2011, American Medical Association (AMA)

    Dr Kim A Papp, Dr Ronald Vender

  51. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

    Article • Journal of the American Academy of Dermatology, April 2011, Elsevier

    Dr Kim A Papp

  52. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

    Article • British Journal of Dermatology, January 2011, Wiley

    Dr Kim A Papp

  53. Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life

    Article • Clinical Drug Investigation, January 2011, Springer Science + Business Media

    Dr Kim A Papp

  54. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis

    Article • International Journal of Dermatology, November 2010, Wiley

    Dr Kim A Papp

  55. Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population

    Article • Journal of Cutaneous Medicine and Surgery, July 2010, SAGE Publications

    Dr Kim A Papp

  56. PSS17 IMPACT OF ADALIMUMAB ON QUALITY OF LIFE AND DEPRESSION IN PSORIASIS PATIENTS: RESULTS FROM PRIDE

    Article • Value in Health, May 2010, Elsevier

    Dr Kim A Papp

  57. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

    Article • Journal of the American Academy of Dermatology, March 2010, Elsevier

    Dr Kim A Papp

  58. Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

    Article • Dermatology, January 2010, Karger Publishers

    Dr Kim A Papp

  59. Patterns of Combination Therapy with Alefacept for the Treatment of Psoriasis in Canada in the AWARE Study

    Article • Journal of Cutaneous Medicine and Surgery, November 2009, Decker, Inc.

    Dr Kim A Papp

  60. Update on Alefacept Safety

    Article • Journal of Cutaneous Medicine and Surgery, November 2009, Decker, Inc.

    Dr Kim A Papp

  61. PSS38 INFLUENCE OF DEPRESSION ON HEALTH RELATED QUALITY OF LIFE IN PSORIASIS: RESULTS FROM AN OPEN LABEL STUDY OF ADALIMUMAB IN PATIENTS WITH PSORIASIS

    Article • Value in Health, October 2009, Elsevier

    Dr Kim A Papp

  62. Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies

    Article • Journal of Cutaneous Medicine and Surgery, September 2009, Decker, Inc.

    Dr Kim A Papp, Dr Ronald Vender

  63. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab

    Article • Archives of Dermatological Research, May 2009, Springer Science + Business Media

    Dr Kim A Papp

  64. PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

    Article • Value in Health, May 2009, Elsevier

    Dr Kim A Papp

  65. PSS21 DISEASE BURDEN AND PRODUCTIVITY LOSS IN A CANADIAN ONLINE SURVEY POPULATION OF INDIVIDUALS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Article • Value in Health, May 2009, Elsevier

    Dr Kim A Papp

  66. Monitoring Patients Treated with Efalizumab or Alefacept

    Article • January 2009, Karger Publishers

    Dr Kim A Papp

  67. PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Article • Value in Health, November 2008, Elsevier

    Dr Kim A Papp

  68. PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL

    Article • Value in Health, November 2008, Elsevier

    Dr Kim A Papp

  69. Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis

    Article • Dermatologic Therapy, November 2008, Wiley

    Dr Kim A Papp

  70. Voclosporin (ISA247) for plaque psoriasis – Authors' reply

    Article • The Lancet, September 2008, Elsevier

    Dr Kim A Papp

  71. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

    Article • The Lancet, April 2008, Elsevier

    Dr Kim A Papp

  72. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Article • Journal of the American Academy of Dermatology, January 2008, Elsevier

    Dr Kim A Papp

  73. Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis

    Article • Drug Safety, January 2008, Springer Science + Business Media

    Dr Kim A Papp

  74. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks

    Article • British Journal of Dermatology, December 2007, Wiley

    Dr Kim A Papp

  75. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis

    Article • British Journal of Dermatology, November 2007, Wiley

    Dr Kim A Papp

  76. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

    Article • British Journal of Dermatology, November 2007, Wiley

    Dr Kim A Papp

  77. The safety of etanercept for the treatment of plaque psoriasis

    Article • Therapeutics and Clinical Risk Management, April 2007, Dove Medical Press

    Dr Kim A Papp

  78. Efalizumab for the Treatment of Psoriatic Arthritis

    Article • Journal of Cutaneous Medicine and Surgery, March 2007, SAGE Publications

    Dr Kim A Papp

  79. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

    Article • Journal of the American Academy of Dermatology, January 2007, Elsevier

    Dr Kim A Papp

  80. CLinical experience acquired with the efalizumab (RaptivaR) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial

    Article • British Journal of Dermatology, July 2006, Wiley

    Dr Kim A Papp

  81. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

    Article • British Journal of Dermatology, June 2006, Wiley

    Dr Kim A Papp

  82. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial

    Article • International Journal of Dermatology, May 2006, Wiley

    Dr Kim A Papp

  83. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

    Article • Journal of the American Academy of Dermatology, April 2006, Elsevier

    Dr Kim A Papp

  84. Long-term management of plaque psoriasis with continuous efalizumab therapy

    Article • Journal of the American Academy of Dermatology, April 2006, Elsevier

    Dr Kim A Papp

  85. Practical guidelines for the long-term treatment of psoriasis with efalizumab

    Article • Journal of the American Academy of Dermatology, April 2006, Elsevier

    Dr Kim A Papp

  86. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis

    Article • Journal of the American Academy of Dermatology, March 2006, Elsevier

    Dr Kim A Papp

  87. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

    Article • Proceedings of the National Academy of Sciences, December 2005, Proceedings of the National Academy of Sciences

    Dr Kim A Papp

  88. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

    Article • Journal of Cutaneous Medicine and Surgery, December 2005, SAGE Publications

    Dr Kim A Papp

  89. Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I

    Article • Journal of Cutaneous Medicine and Surgery, December 2005, SAGE Publications

    Dr Kim A Papp

  90. Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

    Article • Journal of Cutaneous Medicine and Surgery, December 2005, SAGE Publications

    Dr Kim A Papp

  91. An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy

    Article • Clinical Therapeutics, December 2005, Elsevier

    Dr Kim A Papp

  92. A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence

    Article • Journal of Cutaneous Medicine and Surgery, December 2005, SAGE Publications

    Dr Kim A Papp

  93. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

    Article • Journal of Cutaneous Medicine and Surgery, December 2005, SAGE Publications

    Dr Kim A Papp

  94. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

    Article • The Lancet, October 2005, Elsevier

    Dr Kim A Papp

  95. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

    Article • Journal of the American Academy of Dermatology, March 2005, Elsevier

    Dr Kim A Papp

  96. An open-label extension study evaluating the efficacy and safety of oral tazarotene in plaque psoriasis*1

    Article • Journal of the American Academy of Dermatology, March 2004, Elsevier

    Dr Kim A Papp

  97. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis

    Article • Journal of the American Academy of Dermatology, March 2004, Elsevier

    Dr Kim A Papp

  98. Safety of efalizumab in patients with psoriatic arthritis: results of a phase II, randomized, double-blind, placebo-controlled study

    Article • Journal of the American Academy of Dermatology, March 2004, Elsevier

    Dr Kim A Papp

  99. Efalizumab for Patients With Moderate to Severe Plaque Psoriasis

    Article • JAMA, December 2003, American Medical Association (AMA)

    Dr Kim A Papp

  100. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

    Article • Journal of the American Academy of Dermatology, December 2002, Elsevier

    Dr Kim A Papp